ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record14 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05611229Treatment Patterns andOutcomes of TargetedTherapy and ImmunotherapyAmong BRAF-PositiveMelanoma Patients Treatedin the Adjuvant Setting andAmong BRAF-PositiveNovartis PharmaceuticalscompletedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSMelanomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposurePembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureDabrafenibEntry “Dabrafenib+Trametinib”, read b…›Nov 18 · Rule based · ExposureExposureTrametinibEntry “Dabrafenib+Trametinib”, read b…›Nov 18 · Rule based · ExposureExposureIpilimumabEntry “Ipilimumab+Nivolumab”, read by…›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureVemurafenibEntry “Vemurafenib+Cobimetinib”, read…›Nov 18 · Rule based · ExposureExposureCobimetinibEntry “Vemurafenib+Cobimetinib”, read…›Nov 10 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureEncorafenibEntry “Encorafenib+Binimetinib”, read…›Nov 18 · Rule based · ExposureExposureBinimetinibEntry “Encorafenib+Binimetinib”, read…›Nov 18 · Rule based · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nivolumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Nivolumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Exposure
Exposure · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1PembrolizumabClaude Opus 5.5ExposureCurrent
Nov 2NivolumabClaude Opus 5.5ExposureCurrent
Nov 2IpilimumabClaude Opus 5.5ExposureCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10CobimetinibClaude Opus 5.5ExposureCurrent
Nov 18NivolumabRule based · role ruleExposureAgrees
Nov 18PembrolizumabRule based · role ruleExposureAgrees
Nov 18DabrafenibRule based · role ruleExposureCurrent
Nov 18TrametinibRule based · role ruleExposureCurrent
Nov 18IpilimumabRule based · role ruleExposureAgrees
Nov 18VemurafenibRule based · role ruleExposureCurrent
Nov 18CobimetinibRule based · role ruleExposureAgrees
Nov 18EncorafenibRule based · role ruleExposureCurrent
Nov 18BinimetinibRule based · role ruleExposureCurrent
As of nowMelanomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.